NATICK, Mass. – Corindus Vascular Robotics,
a leading developer of precision vascular robotics, today announced that Giora
Weisz, M.D., Director of Clinical Cardiovascular Research at the Center for
Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia
University Medical Center and Associate Professor of medicine at Columbia
University College of Physicians and Surgeons, New York, N.Y. will present his
personal experience using the CorPath® 200 System as part of the CorPath
PRECISE Trial during a scientific presentation “Cath Lab of the Future:
Robotics” at the Cardiovascular Research Technologies annual meeting, CRT2012.
The scientific presentation will take place on Tuesday, February 7 at 2:55 p.m.
in the Palladian Ballroom at the Omni Shoreham Hotel in Washington, D.C.
“Since the early days when Andreas Grüntzigs delivered his
first balloon, not much has changed in the technique we use to perform coronary
percutaneous procedures,” said Dr. Weisz. “For the first time in my career, I
am able to perform interventions without the strain of a heavy lead apron.
Using the CorPath 200 System, I am able to perform percutaneous coronary
interventions (PCI) procedures precisely and effectively, while sitting
comfortably in a radiation protected interventional cockpit. The technology has
the potential to change the standard of care and revolutionize the way we
perform PCI procedures.”
Corindus Vascular Robotics will also host hands-on demonstrations
of the CorPath 200 System at booth 505. To reserve your booth
presentation of the CorPath 200 System, please call 508.653.3335 x200 or email info@corindus.com.
As noted in a recent article published in in the Journal of
Cardiovascular Translational Research, “Robotic-Assisted
Percutaneous Coronary Intervention-Filling an Unmet Need” by Joseph P.
Carrozza, M.D., Professor of Medicine at Tufts University School of Medicine, Vice
President of Cardiovascular Medicine at Steward Healthcare Systems, Chief of
Cardiovascular Medicine at St. Elizabeths Medical Center, the cumulative
exposure to ionizing radiation, orthopedic injuries resulting from lead aprons,
and fatigue from standing for hours during the procedure, makes the
catheterization laboratory a “high-risk workplace” for the interventional
cardiologist. In fact, data published in the Catheterization
and Cardiovascular Intervention journal, an interventional cardiologists
daily exposure to radiation and the physical stresses inherent in the cath lab
can lead to occupational health risks including orthopedic problems, cataracts
and cancer.
The CorPath 200 System allows for controlled
robotic-assisted placement of coronary guidewires and stent/balloon catheters
from an ergonomically optimized interventional cockpit. The lead-lined cockpit
protects the operator from radiation exposure. The comfortable seated position
in front of the cockpit monitors provides enhanced visualization of the
angiography screen while reducing fatigue and minimizes head, neck and back
strain.
“The interest in the interventional cardiology community
continues to reinforce the value of the robotic-assisted PCI,” said David M.
Handler, President and CEO of Corindus. “We are excited with the positive
experience the physicians have had so far using the CorPath 200 System during
the PRECISE trial.”
About Corindus
Corindus is the global technology leader in robotic-assisted percutaneous
coronary interventions. The Companys CorPath® 200 System is the first medical
device that offers interventional cardiologists PCI procedure control from a
radiation shielded interventional cockpit. The CorPath open-platform technology
and intellectual property will enable Corindus to address other segments of the
vascular market, including peripheral, neuro and structural heart applications.
Additional information can be found at: http://www.corindus.com
NOTE: The CorPath 200 System is an investigational device
and limited by federal law to investigational use only.
